Neurogene Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 18, 2024 | Neurogene Inc. |
|---|---|
| By: /s/ Rachel McMinn | |
| Name: Rachel McMinn, Ph.D. | |
| Title: Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Rachel McMinn Rachel McMinn, Ph.D. | Chief Executive Officer, Director | March 18, 2024 |
| /s/ Christine Mikail Christine Mikail, J.D. | President and Chief Financial Officer | March 18, 2024 |
| /s/ Robert Baffi Robert Baffi, Ph.D. | Director | March 18, 2024 |
| /s/ Cory Freedland Cory Freedland, Ph.D. | Director | March 18, 2024 |
| /s/ Sarah B. Noonberg Sarah B. Noonberg, M.D., Ph.D. | Director | March 18, 2024 |
| /s/ Rohan Palekar Rohan Palekar | Director | March 18, 2024 |
| /s/ Robert Keith Woods Robert Keith Woods | Director | March 18, 2024 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.